Revolutionary Treatment has an Astounding 90% Success Rate Against a Deadly Cancer
At the esteemed Hadassah-University Medical Center in Israel, a groundbreaking experimental treatment has emerged with a remarkable 90% success rate in inducing remission for patients afflicted with multiple myeloma.
Hadassah-University Medical Center in Jerusalem's Ein Kerem has recently unveiled a remarkable feat in the realm of cancer treatment. Specifically, they have made an unprecedented breakthrough in treating multiple myeloma cancer, the second most prevalent hematological disease. Comprising a mere 10% of all hematologic malignancies and a meager 1% of all cancerous afflictions, this strain holds a significant place in oncology.
After years of being deemed incurable, a groundbreaking treatment for the disease has emerged from the hospital's bone-marrow transplant and immunotherapy department. This innovative approach was born from a series of meticulously conducted experiments, paving the way for a new era of hope and healing.
Multiple myeloma, a bone marrow malignancy, can wreak havoc on the body's blood cell production by targeting the spongy tissue nestled within select bones. The appellation bestowed upon the affliction known as multiple myeloma stems from the fact that the pernicious malady frequently ravages multiple regions of the corporeal form, such as the cranium, pelvis, ribs, and vertebral column. On numerous occasions, the condition is brought to light through a customary examination of blood or urine, either by suspicion or diagnosis.
Initially, the onset of myeloma may not exhibit any discernible symptoms. However, as the condition progresses, it unleashes a plethora of complications. These include persistent bone pain, debilitation, breathlessness, and fatigue caused by anemia. Furthermore, elevated levels of calcium in the bloodstream can incite a range of symptoms, such as unquenchable thirst, abdominal discomfort, frequent urination, confusion, and constipation. Other symptoms include weight loss, dizziness, blurred vision, and headaches. Additionally, myeloma can lead to recurrent infections, unexplained bruising, and abnormal bleeding. The condition also weakens bones, making them susceptible to fractures, and can cause kidney dysfunction.
The affliction tends to be prevalent among individuals who have surpassed the milestone of 60 years of age. Typically, the diagnosis of multiple myeloma is bestowed upon individuals who have surpassed the septuagenarian threshold, with occurrences being a rarity in those under the age of 40. Furthermore, it is more prevalent in the male demographic and those with a familial lineage that includes multiple myeloma.
Stepensky announced that the esteemed American enterprise, IMMX Bio, has procured a patent license and is on the cusp of commencing a clinical trial within the United States. Our objective is to achieve commercialization and secure FDA approval for our drug within a year.
Decades ago, a revolutionary concept was conceived within the hallowed halls of the Weizmann Institute of Science in Rehovot, under the aegis of Professor Zelig Eshhar's illustrious immunology department. This pioneering notion involved harnessing the power of immune-system cells to combat the nefarious cancer cells that afflict so many. Stepensky has been at the forefront of spearheading the advancement and dissemination of CAR-T therapies. These innovative treatments are designed to reprogram the patient's white blood cells by harnessing healthy cells from the immune system. In the course of the treatment, a meticulous procedure is executed to extract the T cells, the formidable warriors of the immune system that possess the ability to single-handedly combat malignant tumors.
The process of apheresis involves the meticulous separation of donated blood components, effectively isolating the red and white blood cells. The intricate process, spanning a duration of two to four hours, bears a striking resemblance to the conventional act of donating blood. In the Hadassah laboratory, purpose-built to exacting international standards for clean rooms, the T cells undergo a process of engineering that is nothing short of remarkable.
The subsequent phase entails a sophisticated genetic engineering maneuver, whereby a virus is introduced in tandem with a genetic segment that encodes a receptor specifically designed to target the malignant cancer cells. Subsequently, a plethora of meticulously crafted cells are introduced into the individual's body. In a stunning display of medical innovation, the engineered T cells deftly hone in on malignant tumors, obliterating the cancerous cells with surgical precision.
This particular therapy has solely been accessible in China and the United States, with a price tag of nearly $400,000 per patient, and its accessibility is exceedingly restricted.
Stepensky lamented that a mere one-fifth of these nations' population is fortunate enough to receive the aid they so desperately require. Thanks to the groundbreaking work of the esteemed researchers at our esteemed Danny Cunniff Leukemia Research Laboratory, we have achieved a remarkable feat: a significant reduction in the cost of treatment, rendering it both accessible and affordable to those in need.
"Amidst the awe-inspiring outcomes of CAR-T therapies, it appears that a plethora of years brimming with vitality await these fortunate individuals," proclaimed Professor Polina Stepensky, esteemed leader of the department.
The treatment at hand harnesses the power of genetic engineering technology, a revolutionary and efficacious solution for individuals who, until recently, faced a bleak prognosis with a life expectancy of merely two years. Using the revolutionary genetic engineering technique known as CAR-T, or Chimeric Antigen Receptor T-Cell Therapy, the patient's immune system is fortified to vanquish the cancerous cells. The esteemed oncologists have reported that a staggering 90% or more of the 74 patients who received treatment at Hadassah have achieved a state of complete remission.
Stepensky revealed that their waiting list boasts of over 200 patients hailing from Israel and diverse corners of the globe, at any given moment. Owing to the production process's intricacy and the treatment itself, a single patient is admitted each week to undergo the treatment, which is still in its experimental phase.
The eminent Professor Yechezkel Barenholz, a renowned figure in the field of oncology research and esteemed head of the esteemed membrane and liposome research laboratory at Hebrew University-Hadassah Medical School, has lauded the groundbreaking CAR-T technology as a monumental accomplishment. This revolutionary innovation has the potential to significantly streamline the diagnostic process and pave the way for effective treatment.
In a remarkable display of scientific ingenuity, the CAR-T cell treatment has been brought to fruition through the collaborative efforts of Hadassah and the esteemed Prof. Cyrille Cohen, who presides over the immunology and immunotherapy laboratory at Bar-Ilan University in Ramat Gan.
The results at hand are nothing short of dramatic. Stepensky reported a remarkably favorable global response rate, accompanied by negligible and inconsequential side effects. The advent of a potential cure for a disease that has thus far eluded medical science is a monumental source of optimism for patients and healthcare professionals alike.
Within the next several months, the experimental therapy will be made available in all fifty states of the United States.